Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages E2325-E2329

  Nissen, Anne ^a   Christensen, Mikkel ^b   Knop, Filip K ^b   Vilsbøll, Tina ^b   Holst, Jens J ^a   Hartmann, Bolette ^a  

^a Capital Region   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; GLUCOSE BLOOD LEVEL; PEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; MALE; NORMAL HUMAN; OSTEOLYSIS; PRIORITY JOURNAL; BLOOD; BONE; DIET RESTRICTION; DRUG EFFECTS; DRUG THERAPY; GLUCOSE BLOOD LEVEL; METABOLISM; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BONE AND BONES; BONE RESORPTION; COLLAGEN TYPE I; FASTING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; MALE; PEPTIDES; YOUNG ADULT;

EID: 84910016626     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2547     Document Type: Article

References (24)

1. Buffa R, Polak JM, Pearse AG, Solcia E, Grimelius L, Capella C. Identification of the intestinal cell storing gastric inhibitory peptide. Histochemistry. 1975; 43 (3): 249-255.
2. Cataland S, Crockett SE, Brown JC, Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab. 1974; 39 (2): 223-228.
3. Falko JM, Crockett SE, Cataland S, Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab. 1975; 41 (2): 260-265.
4. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000; 85 (10): 3575-3581.
5. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 1993; 133 (6): 2861-2870.
6. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology. 1998; 139 (9): 4004-4007.
7. Zhong Q, Itokawa T, Sridhar S, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2007; 292 (2): E543-E548.
8. Bollag RJ, ZhongQ, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology. 2000; 141 (3): 1228-1235.
9. Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol. 2001; 177: 35-41.
10. Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011; 11: 12.
11. Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone. 2002; 30 (1): 307-313.
12. Clowes JA, Allen HC, Prentis DM, Eastell R, Blumsohn A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab. 2003; 88 (10): 4867-4873.
13. Tsukiyama K, Yamada Y, Yamada C, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol. 2006; 20 (7): 1644-1651.
14. Zhong Q, Ding KH, Mulloy AL, Bollag RJ, Isales CM. Glucosedependent insulinotropic peptide stimulates proliferation and TGF-β release from MG-63 cells. Peptides. 2003; 24 (4): 611-616.
15. Ding KH, Shi XM, Zhong Q, et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res. 2008; 23 (4): 536-543.
16. Xie D, Cheng H, Hamrick M, et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone. 2005; 37 (6): 759-769.
17. Gaudin-Audrain C, Irwin N, Mansur S, et al. Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone. 2013; 53 (1): 221-230.
18. Mieczkowska A, Irwin N, Flatt PR, Chappard D, Mabilleau G. Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone. 2013; 56 (2): 337-342.
19. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucosedependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011; 60 (12): 3103-3109.
20. Clowes JA, Robinson RT, Heller SR, Eastell R, Blumsohn A. Acute changes of bone turnover and PTH induced by insulin and glucose: euglycemic and hypoglycemic hyperinsulinemic clamp studies. J Clin Endocrinol Metab. 2002; 87 (7): 3324-3329.
21. Xu F, Ye YP, Dong YH, Guo FJ, Chen AM, Huang SL. Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. J Huazhong Univ Sci Technolog Med Sci. 2013; 33 (2): 244-249.
22. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res. 2003; 18 (12): 2180-2189.
23. Mabilleau G, Mieczkowska A, Irwin N, Flatt PR, Chappard D. Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor. J Endocrinol. 2013; 219 (1): 59-68.
24. Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2011; 300 (6): E1038-E1046.